Market Closed -
Japan Exchange
11:30:00 24/05/2024 am IST
5-day change
1st Jan Change
1,953
JPY
+0.15%
-2.79%
-3.17%
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ended March 31, 2021
February 05, 2021 at 12:30 pm IST
Zeria Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the full year ended March 31, 2021. For the year, the company expects to report net sales of JPY 57,500 million, operating profit of JPY 4,300 million and profit attributable to owners of parent of JPY 3,700 million or JPY 80.23 per basic share.
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2024, Payable on June 28, 2024
09/05
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2025
09/05
CI
Zeria Pharmaceutical Co., Ltd. Provides Second Quarter and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2025
09/05
CI
Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints
23/04
CI
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3
16/02
MT
Japanese Shares End Firmer on Friday on BoJ Policy Outlook
17/11
MT
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal
17/11
MT
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023
16/11
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
16/11
CI
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses
23/23/23
MT
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024
22/23/22
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024
22/23/22
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024
22/23/22
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
16/23/16
CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 263,900 shares, representing 0.6% for ¥545.29 million.
12/23/12
CI
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024
11/23/11
CI
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024
11/23/11
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024
11/23/11
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
04/23/04
CI
Zeria Pharmaceutical's Attributable Profit Soars 48% in Fiscal Nine Months
21/23/21
MT
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
02/23/02
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
02/23/02
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
06/23/06
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
02/22/02
CI
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of the Year Ending March 31, 2023, Payable on December 1, 2022
02/22/02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
More about the company
Last Close Price
1,950
JPY
Average target price
2,810
JPY
Spread / Average Target
+44.10%
Consensus
1st Jan change
Capi.
-3.17% 547M +18.04% 43.07B +16.92% 21.51B +19.48% 15.19B +19.27% 14.44B +56.12% 13.12B -10.73% 6.79B -0.05% 6.79B -8.87% 5.73B +4.00% 4.73B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ZERIA PHARMACEUTICAL CO., LTD. 
